| Click for the Finfacts Ireland Portal Homepage |

Finfacts Business News Centre

 Irish Economy
 EU Economy
 US Economy
 UK Economy
 Global Economy
 Asia Economy


How to use our RSS feed

Follow Finfacts on Twitter

Web Finfacts

See Search Box lower down this column for searches of Finfacts news pages. Where there may be the odd special character missing from an older page, it's a problem that developed when Interactive Tools upgraded to a new content management system.


Finfacts is Ireland's leading business information site and you are in its business news section.


Finfacts Homepage

Irish Share Prices

Euribor Daily Rates

Irish Economy

Global Income Per Capita

Global Cost of Living

Irish Tax - Income/Corporate

Global News

Bloomberg News

CNN Money

Cnet Tech News


Irish Independent

Irish Times

Irish Examiner

New York Times

Financial Times

Technology News




Content Management by interactivetools.com.

News : Innovation Last Updated: Sep 4, 2014 - 3:04 AM

Novartis of Switzerland may have developed blockbuster heart drug
By Michael Hennigan, Finfacts founder and editor
Sep 1, 2014 - 12:45 AM

Email this article
 Printer friendly page

The results of a study on a heart drug developed by Novartis of Switzerland that were presented in Barcelona on Saturday show that the medicine cut cardiovascular deaths by 20% when compared with a rival treatment, suggesting that the pharmaceutical group may have the prospect of a blockbuster with annual revenues of at least $1bn.

Novartis says that heart failure is the biggest single cause of hospital admissions in adults aged over 65 in the Western world. It affects 26m people worldwide and more than 1m new cases are diagnosed every year.

More people die from heart failure than from some advanced cancers, including breast and bowel cancer. Ageing populations and deteriorating lifestyles mean heart failure is the most rapidly growing cardiovascular condition. One in 5 people aged 40 and over will develop heart failure in their lifetime and the treatment costs are estimated at $65bn a year worldwide.

Despite this, it remains misunderstood. Rather than a sudden, total failure of the heart, it is a progressive weakening characterized by an inability of the heart to pump enough blood around the body. Treatments address symptoms such as fluid retention and breathlessness but there is no cure and survival rates have not improved over the past two decades.

Heart failure has many causes, from high blood pressure, coronary heart disease, kidney disease, diabetes, anemia to common viruses.

On Saturday at the European Society of Cardiology congress in Barcelona and published simultaneously in the New England Journal of Medicine, Novartis revealed that its investigational heart failure medicine, LCZ696, was superior to ACE-inhibitor enalapril on key endpoints in the largest heart failure study ever done, involving more than 8,400 patients. In PARADIGM-HF patients with heart failure with reduced ejection fraction who were given LCZ696 were more likely to be alive and less likely to have been hospitalised for sudden deterioration of their heart failure than those given ACE-inhibitor enalapril. Patients received LCZ696 or enalapril on top of current best treatment.

The magnitude of benefit with LCZ696 against enalapril in HF-REF patients was highly statistically significant and clinically important. In the study, the benefit of LCZ696 was seen early, was sustained and was consistent across subgroups. LCZ696:

  • reduced the risk of death from cardiovascular (CV) causes by 20% (p=0.00004);
  • reduced heart failure hospitalizations by 21% (p=0.00004);
  • reduced the risk of all-cause mortality by 16% (p=0.0005)

Overall there was a 20% risk reduction on the primary endpoint, a composite measure of CV death or heart failure hospitalization (p=0.0000002).

"By demonstrating a very significant reduction in cardiovascular deaths while improving Quality of Life, Novartis' new heart failure medicine, LCZ696, represents one of the most important cardiology advances of the last decade," said David Epstein, division head, Novartis Pharmaceuticals. "We want to thank leading cardiologists from around the world for their collaboration with us and their determination in advancing this important new life saving therapy for heart failure patients."

The Wall Street Journal says that Novartis, Europe's second biggest drugs maker by market capitalization after Swiss rival Roche Holding Ltd., might earn between $2bn and $6bn in peak annual revenue from the drug, according to industry analysts.

The drug has side effects with patients receiving LCZ696 more likely than the enalapril group to experience hypotension, or low blood pressure, though the symptom caused very few patients to drop out of the program. Others experienced coughing, which is also a side effect of enalapril.

Related Articles
Related Articles

© Copyright 2011 by Finfacts.com

Top of Page

Latest Headlines
Digital Taylorism: Amazon's chief rejects depiction of "soulless, dystopian workplace"
Most surviving startups do not grow; Tiny number powers jobs engine
Despite euro dip China & US remain most competitive manufacturing nations
Business startup rates up in most OECD countries led by Australia and UK
NASA's Kepler mission has confirmed the first near-Earth-size planet
Energy subsidies at 6.5% of global GDP; Commodity prices to remain weak
US startups rely on personal savings, debt; Venture capital funds less than 1%
Europe produces 13 $1bn+ "unicorn" startups in one year; London is Europe's digital capital
Irish-based firms raised €120m in VC funding in Q1 2015; Some top recipients Irish for tax purposes
Ireland: Fourth highest 25-34 year old ratio of third-level graduates in developed world: So what?
Business dynamism/ employer firm startups in US secular decline
Innovation Union Scoreboard 2015: Sweden, Denmark, Finland and Germany are on top
Education systems failing to provide students with skills for success in 21st century
US, Switzerland, Denmark, Sweden, Finland have best higher education systems
Handbook of Service Innovation: Ireland moving up the value chain?
Switzerland revives silk industry that thrived for two centuries
Sales of Irish tech firms create 300 millionaires in 15 years and no scaleups
Apple warns of 'material' tax payments from EU's Irish tax investigation
Apple earnings surge 33% on higher price and iPhone sales jump in China
Big Pharma's internationalisation of R&D to China
The dangers of romanticising entrepreneurs despite key role
UK and Irish business R&D heavily reliant on foreign-owned firms
Silicon Valley and the development of the silicon microchip - Part 2
Ireland: Innovation with or without R&D/ scientific breakthroughs
UK government most open/ transparent in world; Ireland & Greece lowest ranking in Europe
10 questions about Switzerland's Solar Impulse aircraft – answered
Silicon Valley loses its silicon; Typical household income stagnates - Part 1
21st century skills are 18 century skills + a computer
Growing ICT sector in Europe accounts for 5% of employment
Should Ireland copy Singapore's scientific research investment plan?
Startups vs Scaleups: 4% of UK startups have 10+ employees 10 years later
Irish patent filings at European Patent Office fell in 2014
Facebook's maze of privacy settings maybe in breach of European law
Apple to invest €1.7bn in Irish and Danish data centres
Silicon Valley insider warns of dodgy $1bn valuations of private companies
Israel's Startup Nation not a jobs engine; Nor is Irish high tech
Established industries often beat new technology investment returns
Ireland: Noonan said EU to drop Apple tax case; Now expects court case
Irish R&D Tax Credit: No evidence of rising business innovation; Facts don't matter
Apple reports biggest profit of a public company in history